Release of uremic retention solutes from protein binding by hypertonic predilution hemodiafiltration: a novel therapeutic approach

E-Poster

https://storage.unitedwebnetwork.com/files/1099/e85f9ffd4768ca52126cc7daec07a990.pdf

Abstract Title

First Name *

Joachim

Last Name *

Jankowski

Co-author 1

Zhuojun Wu zwu@ukaachen.de University Hospital RWTH Aachen

Co-author 2

Vera Jankowski vjankowski@ukaachen.de University Hospital RWTH Aachen

Co-author 3

Co-author 4

Co-author 5

Co-author 6

Co-author 7

Co-author 8

Co-author 9

Co-author 10

Co-author 11

Co-author 12

Co-author 13

Co-author 14

Co-author 15

Introduction

Protein-bound uremic retention solutes accumulate in patients suffering from chronic kidney disease, and hemodialysis removal is hampered. Therefore, we developed a dialysis technique where the protein-bound uremic retention solutes are removed more efficiently under high ionic strength.

Methods

Protein-bound uremic solutes such as phenylacetic acid, indoxyl sulfate and p-cresyl sulfate was combined with plasma in the presence of increased ionic strength.. The protein integrity of proteins and enzymatic activities were analysed. In-vitro dialysis of albumin solution was performed to investigate the clearance of the bound uremic retention solutes. In-vitro hemodiafiltrations of human blood were performed to investigate the influence of increased ionic strength on blood cell survival.

Results

The protein-bound fraction of phenylacetic acid, indoxyl sulfate and p-cresyl sulfate was significantly decreased from 59.4±3.4%, 95.7±0.6%, 96.9±1.5% to 36.4±3.7%, 87.8±0.6% and 90.8±1.3% respectively. The percentage of phenylacetic acid, indoxyl sulfate and p-cresyl sulfate released from protein was 23.0±5.7%, 7.9±1.1% and 6.1±0.2%. The clearance during in-vitro dialysis was increased by 13.1±3.6 %, 68.8±15.1 % and 53.6±10.2 %, respectively. There was no difference in NaCl concentrations at the outlet of the dialyser using isotonic and hypertonic solutions.

Conclusions

In conclusion, this study forms the basis for establishing a novel therapeutic approach to remove the protein-bound retention solutes.

E-Poster Format Requirements

PDF file
Layout: Portrait (vertical orientation)
One page only (Dim A4: 210 x 297mm or PPT)
E-Poster can be prepared in PowerPoint (one (1) PowerPoint slide) but must be saved and submitted as PDF file.
File Size: Maximum file size is 2 Megabytes (2 MB)
No hyperlinks, animated images, animations, and slide transitions
Language: English
Include your abstract number
E-posters can include QR codes, tables and photos